Uveal Melanoma

Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Adjuvant Quisinostat in High-Risk Uveal Melanoma

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Psychoeducation for Uveal Melanoma

Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome